Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease;Acción de quetiapina en dosis bajas sobre las manifestaciones psicóticas, incapacidad motora y estrés del cuidador en pacientes con enfermedad de Parkinson

Revista de Neurologia

Volumn 36, Issue 5, 2003, Pages 401-404

  Giménez Roldán, Santiago ^a   Navarro, E ^a   Mateo, D ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Atypical neuroleptics; Parkinson's disease; Psychosis; Quetiapine; Stress of the caregiver

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CAREGIVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOEHN YAHR DISEASE STAGING; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHWAB ENGLAND SCALE; SLEEP DISORDER; STRESS; SYMPTOMATOLOGY; DYSKINESIA; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT;

AGED; ANTIPSYCHOTIC AGENTS; CAREGIVERS; DIBENZOTHIAZEPINES; DYSKINESIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SLEEP DISORDERS; STRESS;

EID: 0037366161     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3605.2002454     Document Type: Article

References (27)

1. Joel DE, Weiner L. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organisation of the striatum. Neuroscience 2000; 96: 451-74.
2. Factor SA, Molho ES, Friedman JH. Risperidone in Parkinson's disease. Mov Disord 2001; 17: 221-5.
3. Jiménez-Jiménez FJ, Tallón-Barranco A, Ortí-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998; 50: 1183-4.
4. Giménez-Roldán S, Mateo D, Navarro E, Ginés MM. Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Rel Disord 2001; 7: 121-7.
5. Chacón JR, Durán E, Durán JA, Alvarez M. Utilidad de la olanzapina en la psicosis inducida por levodopa en pacientes parkinsonianos. Neurología 2002; 17: 7-11.
6. Factor SA, Friedman JH, Lannon MC. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease. Results of the 12 week openlabel extension in the PSYCLOPS trial. Mov Disord 2001; 16: 135-9.
7. Editorial. Clozapine. Lancet 1989; 1: 1430-2.
8. Dettling M, Cascorb L. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 2001; 58: 93-4.
9. Tarsy D, Baldessarini RJ, Tarazi FL. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 12: 23-45.
10. Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001; 18: 45-61.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington, DC: American Psychiatric Association; 1994.
13. McKeith IG, Fairbaim AF, Bothwell RA, Moore PB, Farrier IN, Thompson P, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: 872-7.
14. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-12.
15. Gancher ST. Scales for the assessment of movement disorders. In Rendón RM, ed. Handbook of neurologic rating scales. New York: Demos Vermande; 1997. p. 81-106.
16. Vilalta-Franch J, Lozano-Gallego M, Hernández-Ferrandiz M, Llinàs-Reglà J, López-Pousa S, López OL. Neuropsychiatric inventory. Propiedades psicométricas de su adaptación al español. Rev Neurol 1999; 29: 15-9.
17. Cummings JL, Mega M, Gray K, Rosemberg-Thompson S, Carusi DA, Gombein J. The neuropsychiatric inventory. Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
18. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
19. Reisberg B, Ferris S, de León M, Crook T. The global deterioration scale for the assessment of primary progressive dementia. Am J Psychiatry 1982; 139: 1136-9.
20. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000; 20: 54-60.
21. Reddy S, Factor SA, Molho E, Feustel PJ. The effect of quetiapine on psychosis and motor functions in parkinsonian patients with and without dementia. Mov Disord 2002; 17: 676-81.
22. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson' disease. Neurology 1995; 45: 669-71.
23. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-9.
24. Fernández HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14: 484-7.
25. Fernández HH. Quetiapine for L-dopa-induced psychosis in Parkinson's disease. Neurology 2000; 55: 899.
26. Wainer WJ, Minagas A, Shulman LM. Quetiapine for L-dopa-induced psychosis in Parkinson's disease. Neurology 2000; 54: 1538.
27. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-22.